FIRE-9 trial: chemo after colon cancer metastasis removal
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and can sign informed consent.
- Your colon or rectal cancer has been proven by a biopsy/pathology test.
- Your metastatic tumors have been fully removed or effectively treated, typically within 3–10 weeks before the trial starts, and the first tumor has also been removed if present.
- Your scans must show no remaining active metastatic cancer at the start (CT and/or MRI within 10 weeks).
- Your overall health is good enough for treatment (ECOG performance status 0–2).
- Your blood tests, liver/kidney function, and heart condition meet the trial limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving patients a type of chemotherapy called FOLFIRI after they have had surgery to remove colorectal cancer that spread to the liver. The goal is to see if this additional treatment helps prevent the cancer from coming back, for patients who could not have a different chemotherapy before surgery.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.